Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer

Cancer Immunology, Immunotherapy

Volumn 60, Issue 7, 2011, Pages 975-984

  Budiu, Raluca A ^a,b   Mantia Smaldone, Gina ^c   Elishaev, Esther ^a,d   Chu, Tianjiao ^b   Thaller, Julia ^b   McCabe, Kathryn ^b   Lenzner, Diana ^e   Edwards, Robert P ^a,b   Vlad, Anda M ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Humoral immunity; Interleukin 2; MUC1 (CA15 3); MUC16 (CA125); Ovarian cancer; Platinum resistance

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; MUCIN 1; MUCIN 16 ANTIGEN; PLATINUM DERIVATIVE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN BLOOD LEVEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD LEVEL; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY PERIOD; TREATMENT RESPONSE;

ADENOCARCINOMA, CLEAR CELL; ANTIBODIES, NEOPLASM; AUTOANTIBODIES; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-2; MEMBRANE PROTEINS; MUCIN-1; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959716214     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1010-x     Document Type: Article

References (41)

1. V Guarneri F Piacentini E Barbieri PF Conte 2010 Achievements and unmet needs in the management of advanced ovarian cancer Gynecol Oncol 117 152 158 20056266 10.1016/j.ygyno.2009.11.033 1:CAS:528:DC%2BC3cXktlCjtbg%3D
2. DW Kufe 2009 Mucins in cancer: function, prognosis and therapy Nat Rev Cancer 9 874 885 19935676 10.1038/nrc2761 1:CAS:528:DC%2BD1MXhsVGlur7F
3. AM Vlad JC Kettel NM Alajez CA Carlos OJ Finn 2004 MUC1 immunobiology: from discovery to clinical applications Adv Immunol 82 249 293 14975259 10.1016/S0065-2776(04)82006-6 1:CAS:528:DC%2BD2cXivFCju74%3D (Pubitemid 38209513)
4. MA Cheever JP Allison AS Ferris OJ Finn BM Hastings TT Hecht I Mellman SA Prindiville JL Viner LM Weiner LM Matrisian 2009 The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res 15 5323 5337 19723653 10.1158/1078-0432.CCR-09-0737
5. VJ Hunter L Daly M Helms JT Soper A Berchuck DL Clarke-Pearson RC Bast Jr 1990 The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction Am J Obstet Gynecol 163 1164 1167 2171337 1:STN:280:DyaK3M%2Fit1ylsw%3D%3D (Pubitemid 20377391)
6. SC Chauhan AP Singh F Ruiz SL Johansson M Jain LM Smith N Moniaux SK Batra 2006 Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) Mod Pathol 19 1386 1394 16880776 10.1038/modpathol.3800646 1:CAS:528:DC%2BD28Xps1Oqu70%3D (Pubitemid 44423087)
7. RC Bast Jr M Feeney H Lazarus LM Nadler RB Colvin RC Knapp 1981 Reactivity of a monoclonal antibody with human ovarian carcinoma J Clin Invest 68 1331 1337 7028788 10.1172/JCI110380 (Pubitemid 12235035)
8. AM Vlad RA Budiu DE Lenzner Y Wang JA Thaller K Colonello PA Crowley-Nowick JL Kelley FV Price RP Edwards 2010 A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer Cancer Immunol Immunother 59 293 301 19690855 10.1007/s00262-009-0750-3 1:CAS:528:DC%2BD1MXhsVajurvP
9. AN Gordon BC Schultes H Gallion R Edwards TL Whiteside JM Cermak CF Nicodemus 2004 CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients Gynecol Oncol 94 340 351 15297171 10.1016/j.ygyno.2004.04.024 1:CAS:528:DC%2BD2cXmsVeqtrg%3D (Pubitemid 39024536)
10. J Pfisterer A du Bois J Sehouli S Loibl S Reinartz A Reuss U Canzler A Belau C Jackisch R Kimmig K Wollschlaeger V Heilmann F Hilpert 2006 The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR Ann Oncol 17 1568 1577 17005631 10.1093/annonc/mdl357 1:STN:280:DC%2BD28nos1Cjtw%3D%3D (Pubitemid 44548850)
11. AW Silk RE Schoen DM Potter OJ Finn 2009 Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer Mol Immunol 47 52 56 19217667 10.1016/j.molimm.2008.12.025
12. AJ Lepisto AJ Moser H Zeh K Lee D Bartlett JR McKolanis BA Geller A Schmotzer DP Potter T Whiteside OJ Finn RK Ramanathan 2008 A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors Cancer Ther 6 955 964 19129927 1:CAS:528:DC%2BD1MXmsFSmtrg%3D
13. RK Ramanathan KM Lee J McKolanis E Hitbold W Schraut AJ Moser E Warnick T Whiteside J Osborne H Kim R Day M Troetschel OJ Finn 2005 Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer Cancer Immunol Immunother 54 254 264 15372205 10.1007/s00262-004-0581-1 1:CAS:528:DC%2BD2MXjs1ahuw%3D%3D (Pubitemid 40174243)
14. DG Rosen L Wang JN Atkinson Y Yu KH Lu EP Diamandis I Hellstrom SC Mok J Liu RC Bast Jr 2005 Potential markers that complement expression of CA125 in epithelial ovarian cancer Gynecol Oncol 99 267 277 16061277 10.1016/j.ygyno. 2005.06.040 1:CAS:528:DC%2BD2MXhtFKhsrfM (Pubitemid 41502830)
15. JacobsI BJR 1989 CA125 tumour-associated antigen: a review of the literature Hum Reprod 4 1 12
16. DG Rosen X Huang MT Deavers A Malpica EG Silva J Liu 2004 Validation of tissue microarray technology in ovarian carcinoma Mod Pathol 17 790 797 15073602 10.1038/modpathol.3800120 1:CAS:528:DC%2BD2cXmsVOis7s%3D (Pubitemid 38843361)
17. D Al-azawi G Kelly E Myers EW McDermott AD Hill MJ Duffy NO Higgins 2006 CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer BMC Cancer 6 220 16953875 10.1186/1471-2407-6-220 (Pubitemid 44509018)
18. MJ Duffy C Duggan R Keane AD Hill E McDermott J Crown N O'Higgins 2004 High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer Clin Chem 50 559 563 14726467 10.1373/clinchem.2003.025288 1:CAS:528:DC%2BD2cXhvVChsrs%3D (Pubitemid 38297306)
19. M Markman M Federico PY Liu E Hannigan D Alberts 2006 Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer Gynecol Oncol 103 195 198 16595148 10.1016/j.ygyno.2006.02.024 1:CAS:528:DC%2BD28Xps1Wmsro%3D (Pubitemid 44389869)
20. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB (2008) Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 22(3):393-402
21. Jeong IG, Han KS, Joung JY, Choi WS, Hwang SS, Yang SO, Seo HK, Chung J, and Lee KH (2007) Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival. J Korean Med Sci 22(Suppl):S122-S128
22. E Sato SH Olson J Ahn B Bundy H Nishikawa F Qian AA Jungbluth D Frosina S Gnjatic C Ambrosone J Kepner T Odunsi G Ritter S Lele YT Chen H Ohtani LJ Old K Odunsi 2005 Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc Natl Acad Sci USA 102 18538 18543 16344461 10.1073/pnas.0509182102 1:CAS:528:DC%2BD28Xpt1Om (Pubitemid 43011261)
23. M Reuschenbach M von Knebel Doeberitz N Wentzensen 2009 A systematic review of humoral immune responses against tumor antigens Cancer Immunol Immunother 58 1535 1544 19562338 10.1007/s00262-009-0733-4 1:CAS:528: DC%2BD1MXptVentr4%3D
24. O Egeter R Mocikat K Ghoreschi A Dieckmann M Rocken 2000 Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice Cancer Res 60 1515 1520 10749115 1:CAS:528: DC%2BD3cXit1aqtrs%3D (Pubitemid 30183417)
25. NN Hunder H Wallen J Cao DW Hendricks JZ Reilly R Rodmyre A Jungbluth S Gnjatic JA Thompson C Yee 2008 Treatment of metastatic melanoma with autologous CD4 + T cells against NY-ESO-1 N Engl J Med 358 2698 2703 18565862 10.1056/NEJMoa0800251 1:CAS:528:DC%2BD1cXns1ajtrw%3D (Pubitemid 351860862)
26. N Muller-Hermelink H Braumuller B Pichler T Wieder R Mailhammer K Schaak K Ghoreschi A Yazdi R Haubner CA Sander R Mocikat M Schwaiger I Forster R Huss WA Weber M Kneilling M Rocken 2008 TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis Cancer Cell 13 507 518 18538734 10.1016/j.ccr.2008.04.001 (Pubitemid 351763899)
27. A Lanzavecchia 1985 Antigen-specific interaction between T and B cells Nature 314 537 539 3157869 10.1038/314537a0 1:STN:280:DyaL2M7ovVaktg%3D%3D (Pubitemid 15124262)
28. KL Rock B Benacerraf AK Abbas 1984 Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors J Exp Med 160 1102 1113 6207262 10.1084/jem.160.4.1102 1:CAS:528:DyaL2cXmtVykurg%3D (Pubitemid 14020970)
29. A Cerutti H Zan A Schaffer L Bergsagel N Harindranath EE Max P Casali 1998 CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM + IgD + B cell line J Immunol 160 2145 2157 9498752 1:CAS:528:DyaK1cXhtlertbg%3D (Pubitemid 28119893)
30. S Romagnani 1997 The Th1/Th2 paradigm Immunol Today 18 263 266 9190109 10.1016/S0167-5699(97)80019-9 1:CAS:528:DyaK2sXktVKhtr4%3D (Pubitemid 27261442)
31. M Terabe JM Park JA Berzofsky 2004 Role of IL-13 in regulation of anti-tumor immunity and tumor growth Cancer Immunol Immunother 53 79 85 14610620 10.1007/s00262-003-0445-0 1:CAS:528:DC%2BD3sXpvVektr8%3D (Pubitemid 38161213)
32. EV Hogdall CK Hogdall J Blaakaer NH Heegaard E Glud L Christensen JE Bock B Norgaard-Pedersen A Wiik SK Kjaer 2002 P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis Apmis 110 545 553 12390412 10.1034/j.1600-0463.2002.11007805.x
33. K Odunsi AA Jungbluth E Stockert F Qian S Gnjatic J Tammela M Intengan A Beck B Keitz D Santiago B Williamson MJ Scanlan G Ritter YT Chen D Driscoll A Sood S Lele LJ Old 2003 NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer Cancer Res 63 6076 6083 14522938 1:CAS:528:DC%2BD3sXnvVSitLo%3D (Pubitemid 37187513)
34. AL Oei M Moreno RH Verheijen FC Sweep CM Thomas LF Massuger S von Mensdorff-Pouilly 2008 Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer Int J Cancer 123 1848 1853 18661524 10.1002/ijc.23725 1:CAS:528:DC%2BD1cXhtFKhu7fO
35. Y Hamanaka Y Suehiro M Fukui K Shikichi K Imai Y Hinoda 2003 Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer Int J Cancer 103 97 100 12455059 10.1002/ijc.10801 1:CAS:528: DC%2BD38Xptl2htrk%3D (Pubitemid 35424210)
36. Y Hirasawa N Kohno A Yokoyama K Kondo K Hiwada M Miyake 2000 Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer Am J Respir Crit Care Med 161 589 594 10673204 1:STN:280:DC%2BD3c7otVaksQ%3D%3D (Pubitemid 30129471)
37. S von Mensdorff-Pouilly AA Verstraeten P Kenemans FG Snijdewint A Kok GJ Van Kamp MA Paul PJ Van Diest S Meijer J Hilgers 2000 Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin J Clin Oncol 18 574 583 (Pubitemid 30078538)
38. DW Cramer L Titus-Ernstoff JR McKolanis WR Welch AF Vitonis RS Berkowitz OJ Finn 2005 Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer Cancer Epidemiol Biomarkers Prev 14 1125 1131 15894662 10.1158/1055-9965.EPI-05-0035 1:CAS:528:DC%2BD2MXktFCksb8%3D (Pubitemid 40656457)
39. GJ Rustin RC Bast Jr GJ Kelloff JC Barrett SK Carter PD Nisen CC Sigman DR Parkinson RW Ruddon 2004 Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer Clin Cancer Res 10 3919 3926 15173101 10.1158/1078-0432.CCR-03-0787 1:CAS:528:DC%2BD2cXksVKntLs%3D (Pubitemid 38697628)
40. GJ Rustin AE Nelstrop P McClean MF Brady WP McGuire WJ Hoskins H Mitchell HE Lambert 1996 Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 J Clin Oncol 14 1545 1551 8622070 1:CAS:528: DyaK28XjtFKisLY%3D (Pubitemid 26134212)
41. GJ Rustin AE Nelstrop MK Tuxen HE Lambert 1996 Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study Ann Oncol 7 361 364 8805927 1:STN:280:DyaK28zpvFCgtg%3D%3D (Pubitemid 26246787)